

Contents

List of Contributors	<i>XIII</i>
Preface	<i>XVII</i>
A Personal Foreword	<i>XIX</i>

Part One Scaffolds: Identification, Representation Diversity, and Navigation 1

1 Identifying and Representing Scaffolds 3

Nathan Brown

1.1	Introduction	3
1.2	History of Scaffold Representations	4
1.3	Functional versus Structural Molecular Scaffolds	7
1.4	Objective and Invariant Scaffold Representations	7
1.4.1	Molecular Frameworks	7
1.4.2	Scaffold Tree	8
1.5	Maximum Common Substructures	9
1.6	Privileged Scaffolds	11
1.7	Conclusions	11
	References	12

2 Markush Structures and Chemical Patents 15

David Anthony Cosgrove

2.1	Introduction	15
2.2	Encoding Markush Structures	18
2.2.1	The <i>r_group</i> Record	19
2.2.1.1	Exact R Groups	19
2.2.1.2	Inexact R Groups	19
2.2.1.3	Fused R Groups	19
2.2.2	The Menguin Program	20
2.2.3	Correspondence between the MIL File and the Markush Structure	21
2.3	The Search Algorithm	22
2.3.1	Matching R Groups	25

2.3.1.1	Exact R Groups	25
2.3.1.2	Inexact R Groups	27
2.3.1.3	Fused R Groups	28
2.3.1.4	Hydrogen Atoms	29
2.3.1.5	Managing Multiple Fragment/R Group Matches	30
2.4	Using Periscope for Scaffold Hopping	31
2.4.1	Substructure Searching	32
2.4.2	Free–Wilson Analysis	33
2.4.3	Fast Followers	36
2.5	Conclusions	36
	References	37
3	Scaffold Diversity in Medicinal Chemistry Space	39
	<i>Sarah R. Langdon, Julian Blagg, and Nathan Brown</i>	
3.1	Introduction	39
3.1.1	Scaffold Representation	39
3.1.2	What Do We Mean by Scaffold Diversity?	41
3.2	Scaffold Composition of Medicinal Chemistry Space	41
3.2.1	Natural Products as a Source of Novel Medicinal Chemistry Scaffolds	45
3.2.2	Enumerating Potential Medicinal Chemistry Scaffolds	46
3.2.3	Using Scaffold Composition to Interpret Bioactivity Data	48
3.3	Metrics for Quantifying the Scaffold Diversity of Medicinal Chemistry Space	48
3.4	Visualizing the Scaffold Diversity of Medicinal Chemistry Space	53
3.5	Conclusions	56
	References	57
4	Scaffold Mining of Publicly Available Compound Data	61
	<i>Ye Hu and Jürgen Bajorath</i>	
4.1	Introduction	61
4.2	Scaffold Definition	62
4.3	Selectivity of Scaffolds	63
4.3.1	Privileged Substructures	63
4.3.2	Target Community-Selective Scaffolds	64
4.3.3	Target-Selective Scaffolds	67
4.4	Target Promiscuity of Scaffolds	67
4.4.1	Promiscuous BM Scaffolds and CSKs	67
4.4.2	Scaffold–Target Family Profiles	70
4.4.3	Promiscuous Scaffolds in Drugs	70
4.5	Activity Cliff-Forming Scaffolds	71
4.5.1	Activity Cliff Concept	71
4.5.2	Multitarget Cliff-Forming Scaffolds	71
4.6	Scaffolds with Defined Activity Progression	73
4.6.1	Activity Profile Sequences	73

4.6.2	Conserved Scaffolds	75
4.7	Scaffold Diversity of Pharmaceutical Targets	76
4.7.1	Scaffold Hopping Potential	76
4.7.2	Structural Relationships between Scaffolds	76
4.7.3	Scaffold Hopping in Virtual Screening	78
4.8	Conclusions	79
	References	80
5	Exploring Virtual Scaffold Spaces	83
	<i>William R. Pitt and Boris Kroeplien</i>	
5.1	Introduction	83
5.1.1	Virtual Chemistry	83
5.1.2	Chemical Space	83
5.1.3	Scaffold Definition	84
5.2	The Comprehensive Enumeration of Parts of Chemical Space	85
5.2.1	Fragments	85
5.2.2	Ring Systems	86
5.2.3	Reagents	87
5.3	The Iterative Generation of Virtual Compounds	88
5.3.1	Transformations	88
5.3.2	Manual Selection of Chemical Modifications	88
5.3.3	Analog Generators	89
5.3.4	Inverse QSAR	89
5.3.5	Multiple Objective Optimization	90
5.3.6	Structure-Based De Novo Design	90
5.4	Virtual Synthesis	92
5.4.1	Synthetic Tractability	92
5.4.2	Using Real-Life Reactions for in Silico Molecule Construction	93
5.4.3	Readily Synthesizable Compounds	94
5.4.3.1	Construction	94
5.4.3.2	Searching	95
5.4.3.3	Outside Big Pharma	96
5.4.4	Iterative Approaches	96
5.5	Visualizations of Scaffold Space	96
5.6	A Perspective on the Past and the Future	97
	References	99
Part Two	Scaffold-Hopping Methods	105
6	Similarity-Based Scaffold Hopping Using 2D Fingerprints	107
	<i>Peter Willett</i>	
6.1	Fingerprints	107
6.2	Retrospective Studies of Scaffold Hopping Using 2D Fingerprints	109

6.3	Predictive Studies of Scaffold Hopping Using 2D Fingerprints	112
6.4	Conclusions	114
	References	115
7	CATS for Scaffold Hopping in Medicinal Chemistry	119
	<i>Christian P. Koch, Michael Reutlinger, Nickolay Todoroff, Petra Schneider, and Gisbert Schneider</i>	
7.1	Chemically Advanced Template Search	119
7.2	Retrospective Evaluation of Enrichment and Scaffold Hopping Potential	122
7.3	Prospective Scaffold-Hopping Applications	126
7.4	Conclusions	128
	References	128
8	Reduced Graphs	131
	<i>Kristian Birchall</i>	
8.1	Introduction	131
8.2	Generating Reduced Graphs	133
8.2.1	Reduction Scheme	133
8.2.2	Node Labeling	134
8.2.3	Sheffield Implementations	135
8.2.4	Extended Reduced Graphs	136
8.3	Comparison and Usage of Reduced Graphs	137
8.3.1	Conventional Fingerprinting	138
8.3.2	RG-Specific Fingerprints	139
8.3.3	Augmenting Fingerprints with Edit Distance	140
8.3.4	Extended Reduced Graph Fingerprints	141
8.3.5	Graph Matching Approaches	143
8.3.6	Bioisostere Encoding	144
8.4	Summary	146
	References	146
9	Feature Trees	149
	<i>Nathan Brown</i>	
9.1	Introduction	149
9.2	Feature Tree Generation	149
9.3	Feature Tree Comparison	150
9.4	Retrospective Validation	151
9.5	Implementations and Applications	152
9.5.1	MTree: Combinations of Query Molecules	152
9.5.2	Similarity Searching in Large Combinatorial Chemistry Spaces	152
9.6	Conclusions	153
	References	154

10	Feature Point Pharmacophores (FEPOPS)	155
	<i>Jeremy L. Jenkins</i>	
10.1	Similarity Searching in Drug Discovery	155
10.2	FEPOPS: An Analogy to Image Compression	157
10.3	Computing FEPOPS	159
10.4	Scaling and Correlations	162
10.5	Defining Scaffold Hopping	163
10.6	FEPOPS in Similarity Searching and Scaffold Hopping	164
10.7	Alternative Alignment	168
10.8	<i>In Silico</i> Target Prediction	170
10.9	Chemical Space Uniqueness	171
10.10	Perspective on FEPOPS' 10 Year Anniversary	172
	References	173
11	Three-Dimensional Scaffold Replacement Methods	175
	<i>Nathan Brown</i>	
11.1	Introduction	175
11.2	Generic Three-Dimensional Scaffold Replacement Workflow	175
11.2.1	Molecule Databases	175
11.2.2	Fragment Generation and Filtering	177
11.2.3	Fragment Replacement Search and Scoring	178
11.3	SHOP: Scaffold HOPping by GRID-Based Similarity Searches	178
11.4	ReCore	179
11.5	BROOD	179
11.6	Conclusions	180
	References	181
12	Spherical Harmonic Molecular Surfaces (ParaSurf and ParaFit)	183
	<i>David W. Ritchie and Violeta I. Pérez-Nueno</i>	
12.1	Introduction	183
12.2	Spherical Harmonic Surfaces	183
12.3	Rotating Spherical Polar Fourier Expansions	185
12.4	Spherical Harmonic Surface Shape Similarity	186
12.5	Calculating Consensus Shapes and Center Molecules	187
12.6	The ParaSurf and ParaFit Programs	188
12.7	Using Consensus Shapes to Probe the CCR5 Extracellular Pocket	190
12.8	Conclusions	192
	References	193
13	The XED Force Field and Spark	195
	<i>Martin Slater and Andy Vinter</i>	
13.1	Pharmacological Similarity – More than Just Chemical Structure	195
13.2	Improving the Generation of Valid Molecular Fields	199

13.3	The eXtended Electron Distribution (XED) Force Field	200
13.4	The XED Force Field Applied to Scaffold Hopping in Spark	202
13.5	How Spark Works	202
13.6	Application of Spark in Drug Discovery Scenarios	206
13.7	P38 Kinase Inhibitor Fragment Growing Using Spark	207
13.7.1	The Beauty of P38	207
13.8	Creating New Molecules	208
13.9	New Potential Inhibitors	210
13.10	The Far-Reaching Consequences of Using Molecular Fields as Measures of Similarity	212
	References	213
14	Molecular Interaction Fingerprints	215
	<i>Didier Rognan and Jérémy Desaphy</i>	
14.1	Introduction	215
14.2	Target-Annotated Ligand Fingerprints	215
14.2.1	Interacting Atom/Fragment Fingerprints	216
14.2.2	Protein–Ligand Pharmacophores	217
14.3	Ligand-Annotated Target Fingerprints	217
14.4	True Target–Ligand Fingerprints	220
14.4.1	Association Fingerprints	220
14.4.2	Interaction Pattern Fingerprints	222
14.5	Conclusions	225
	References	226
15	SkelGen	231
	<i>Nikolay P. Todorov</i>	
15.1	Introduction	231
15.2	Structure Generation and Optimization	232
15.2.1	Fragments and Fragment Sets	232
15.2.2	Structure Generation	234
15.2.3	Scoring and Optimization	234
15.2.4	Ligand-Based Design	234
15.3	Validation Studies	235
15.3.1	Retrospective Validation Study: CDK2, COX2, ER, MMP-3	235
15.3.2	Estrogen Receptor	235
15.3.3	Histamine H3 Inverse Agonists	236
15.4	Scaffold Hopping Using Fixed Fragments	237
15.5	Scaffold Hopping Using Site Points	238
15.6	Further Considerations for Scaffold Hopping	240
15.6.1	Receptor Flexibility	240
15.6.2	Water Molecules	241
15.6.3	Receptor Specificity	242
15.7	Conclusion	242
	References	243

Part Three Case Studies 245**16 Case Study 1: Scaffold Hopping for T-Type Calcium Channel and Glycine Transporter Type 1 Inhibitors 247***Leah C. Konkol, Timothy J. Senter, and Craig W. Lindsley*

- 16.1 Introduction 247
- 16.2 T-Type Calcium Channel Inhibitors 248
- 16.3 Scaffold Hopping to Access Novel Calcium T-Type Channel Inhibitors 250
- 16.4 Scaffold Hopping to Access Novel Glycine Transporter Type 1 (GlyT1) Inhibitors 253
- 16.5 Conclusions 255
- References 255

17 Case Study 2: Bioisosteric Replacements for the Neurokinin 1 Receptor (NK1R) 259*Francesca Perruccio*

- 17.1 Introduction 259
- 17.2 Neurokinin 1 (NK₁) Therapeutic Areas 259
- 17.3 The Neurokinin 1 Receptor (NK₁R) and Its Mechanism 260
- 17.4 Neurokinin 1 Antagonists 261
- 17.5 NK₁ Receptor: Target Active Site and Binding Mode 264
- 17.6 Bioisosteric Replacements in NK₁ Receptor Antagonist 266
- 17.7 Bioisosteric Replacements in NK₁ Receptor Antagonist: A Retrospective Study 270
- 17.8 Summary and Conclusions 274
- References 274

18 Case Study 3: Fragment Hopping to Design Highly Potent and Selective Neuronal Nitric Oxide Synthase Inhibitors 279*Haitao Ji and Richard B. Silverman*

- 18.1 Fragment-Based Drug Design 279
- 18.2 Minimal Pharmacophoric Elements and Fragment Hopping 281
- 18.3 Fragment Hopping to Design Novel Inhibitors for Neuronal Nitric Oxide Synthase 283
- 18.4 Fragment Hopping to Optimize Neuronal Nitric Oxide Synthase Inhibitors 288
- 18.5 Application of Neuronal Nitric Oxide Synthase Inhibitors to the Prevention of Cerebral Palsy 289
- References 291

Index 297

